Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 91-100 of 134 for

Edit search filters
  1. Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

    Rochester, MN

  2. Understanding the Challenges, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials in Minority Patient Populations

    Jacksonville, FL, Scottsdale/Phoenix, AZ, Rochester, MN

  3. Melanoma Relatlimab Nivolumab

    Jacksonville, FL, Rochester, MN

  4. Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

    Rochester, MN

  5. MC1R-targeted Alpha-particle Monotherapy And Combination Therapy Trial With Nivolumab In Adults With Advanced Melanoma

    Rochester, MN, Jacksonville, FL

  6. A Study to Evaluate the DermaSensor Tool on Skin Lesions Suggestive of Skin Cancer

    Rochester, MN

  7. A Study to Better Understand How to Predict and Manage Patients Who are at High Risk for Developing Rheumatic Immune-related Adverse Events While Receiving Treatment for Melanoma

    Rochester, MN

  8. Spatial and Molecular Architecture of Tumor Environments Responsive to IO (immuno-oncology) Therapy

    Rochester, MN

  9. A Study to Evaluate Immunotherapy and Ovarian Function Among Pre-menopausal Melanoma Survivors

    Rochester, MN

  10. Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

    Rochester, MN

.

Mayo Clinic Footer